Overview Quote
Stock Activity
| Day Low - High | 20.11 - 20.79 |
| 52wk Low - High | 13.85 - 25.67 |
| Previous Close | 20.21 |
| Avg. Volume | 111,905 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 436.03 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.65 |
| P/E (F1) | 0.00 |
| Current Year Est. | -0.64 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
105 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Company Description
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the company's key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.Combidex?, the company's other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.16 | -0.17 | -0.64 | -0.11 |
| Number of Estimates | 4 | 4 | 6 | 5 |
| Low Estimate | -0.18 | -0.23 | -0.75 | -0.23 |
| High Estimate | -0.14 | -0.12 | -0.56 | NA |
| Year Ago EPS | 0.18 | -0.16 | -0.68 | -0.64 |
| EPS Growth | -187.50% | -6.25% | 5.64% | 82.55% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| AMAG PHARMA INC | AMAG | 20.21 | ![]() |
![]() |
| AETERNA ZENTARS | AEZS | 1.90 | ![]() |
![]() |
| ANIKA THERAPEUT | ANIK | 16.55 | ![]() |
![]() |
| BIOGEN IDEC INC | BIIB | 207.75 | ![]() |
![]() |
| PROTALIX BIOTHR | PLX | 5.04 | ![]() |
![]() |
| AASTROM BIOSCI | ASTM | 0.51 | ![]() |
![]() |
| ADDEX THERA LTD | ADDXF | 3.95 | ![]() |
![]() |
| AFFYMAX INC | AFFY | 1.09 | ![]() |
![]() |
| ALEXION PHARMA | ALXN | 91.32 | ![]() |
![]() |
| ALNYLAM PHARMA | ALNY | 29.69 | ![]() |
![]() |
Sector:Medical>> Industry:MED-BIOMED/GENE
Zacks Commentary
Label Expansion Sought for AMAG/TKPYY's Rienso
Jun 10, 2013
The Zacks Analyst Blog Highlights: AMAG Pharmaceuticals, Takeda Pharmaceutical, DISH Network, Sprint Nextel and Verizon Communications
May 23, 2013
Swiss Issue for AMAG/Takeda's Rienso
May 22, 2013
AMAG Narrows Loss; Maintains View
Apr 24, 2013
Positive Results on AMAG's Feraheme
Mar 18, 2013
FDA Action Date for AMAG Drug
Mar 11, 2013
AMAG Narrows Loss, Maintains View
Mar 04, 2013
AMAG Gives 4Q12 Snapshot
Jan 07, 2013
Financials
| EPS TTM | -0.30 |
| Sales | 85 |
| Net Income | -8 |
| Price/Earnings | NA |
| Price/Book | 2.54 |
| Price/Cash Flow | NA |
| Price/Sales | 4.97 |
News
Iron Deficiency Anemia - Pipeline Review, H1 2013 - M2
Jun 18, 2013
Takeda submits type-II variation for anemia drug - Datamonitor
Jun 18, 2013
Shares of AMAG Pharmaceuticals Under Pressure, Down 1.3% - Financial News Network Online - Market Movers
Jun 14, 2013
AMAG Pharmaceuticals (AMAG) Trading Near $20.87 Resistance Level - Freshbrewedmedia
Jun 11, 2013
Access Pharma, AMAG Announce US License Deal for MuGard - Benzinga
Jun 10, 2013
AMAG Pharmaceuticals Announces Submission of a Type II Variation for Rienso Label Expansion in Europe to Include All Adult Iron Deficiency Anemia Patients Who Cannot Take Oral Iron - Globenewswire
Jun 7, 2013
AMAG announces encouraging data from Phase III IDA sub-group analysis - Datamonitor
Jun 7, 2013
Shares of AMAG Pharmaceuticals Receive a Boost, Up 1.8% - Financial News Network Online - Market Movers
Jun 7, 2013
Broker Recommendations
| Current ABR | 2.50 |
| ABR (Last Week) | 2.50 |
| # of recs in ABR | 6 |
| Average Target Price | 20.67 |
| Industry Rank by ABR | 105 out of 265 |
| Rank in Industry | 31 out of 153 |

